Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.98 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35
Open 49.98
Bid (Size) 49.85 (1)
Ask (Size) 50.25 (1)
Prev. Close 49.98
Today's Range 49.98 - 49.98
52wk Range 48.25 - 81.42
Shares Outstanding 2,222,113,553
Dividend Yield 4.56%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
From Bristol Myers Squibb
Via Business Wire
Can Bristol Myers Squibb Keep Its Streak Alive?
Bristol Myers Squibb is a $100 billion market cap pharmaceutical company that has raised its dividend every year since 2010 and has paid one since 1933. 
Via Talk Markets

Performance

YTD
-30.83%
-30.83%
1 Month
-5.32%
-5.32%
3 Month
-17.58%
-17.58%
6 Month
-22.72%
-22.72%
1 Year
-38.07%
-38.07%

More News

Read More
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Via Benzinga
Exposures Product Safety
3 stocking stuffers you can buy for yourself
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Exploring NYSE:BMY's dividend characteristics.
Via Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
Why Is Avidity Biosciences (RNA) Stock Up 15% Today?
Via InvestorPlace
Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
Via InvestorPlace
Why Bristol Myers Squibb Stock Is Fading Today
Via The Motley Fool
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
Via The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
Via InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Via Benzinga
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
Via InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
Via InvestorPlace
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Via InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
Via Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.